|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00403962 |
The purpose of this study is to assess the efficacy, safety and tolerability of a combination of Vestipitant and Paroxetine in patients with Social Anxiety Disorder (SAD)
Condition | Intervention | Phase |
Social Anxiety Disorder |
Drug: vestipitant/paroxetine |
Phase II |
MedlinePlus related topics: | Anxiety |
ChemIDplus related topics: | Paroxetine Paroxetine hydrochloride Paroxetine Mesylate Vestipitant |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine Combination or Paroxetine Monotherapy to Placebo in Patients With Social Anxiety Disorder (SAD) |
Estimated Enrollment: | 204 |
Study Start Date: | October 2004 |
Ages Eligible for Study: | 18 Years to 64 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Denmark | |||||
GSK Clinical Trials Call Center | |||||
Kopenhagen K, Denmark, 1256 | |||||
GSK Clinical Trials Call Center | |||||
Kopenhagen O, Denmark, 2100 | |||||
GSK Clinical Trials Call Center | |||||
Hillerod, Denmark, 3400 | |||||
GSK Clinical Trials Call Center | |||||
Risskov, Denmark, 8240 | |||||
GSK Clinical Trials Call Center | |||||
Skanderborg, Denmark, DK-8660 | |||||
GSK Clinical Trials Call Center | |||||
Hvidovre, Denmark, 2650 | |||||
GSK Clinical Trials Call Center | |||||
Soro, Denmark, 4180 | |||||
Germany | |||||
GSK Clinical Trials Call Center | |||||
Berlin, Germany, 10629 | |||||
GSK Clinical Trials Call Center | |||||
Berlin, Germany, 13053 | |||||
Germany, Hessen | |||||
GSK Clinical Trials Call Center | |||||
Huttenberg, Hessen, Germany, 35625 | |||||
Germany, Niedersachsen | |||||
GSK Clinical Trials Call Center | |||||
Achim, Niedersachsen, Germany, 28832 | |||||
Norway | |||||
GSK Clinical Trials Call Center | |||||
Bergen, Norway, N-5068 | |||||
GSK Clinical Trials Call Center | |||||
Sandvika, Norway, 1338 | |||||
GSK Clinical Trials Call Center | |||||
Oslo, Norway, N-0364 | |||||
GSK Clinical Trials Call Center | |||||
Hamar, Norway, 2317 | |||||
South Africa | |||||
GSK Clinical Trials Call Center | |||||
Tygerberg, South Africa, 7505 | |||||
GSK Clinical Trials Call Center | |||||
Bloemfontein, South Africa |
GlaxoSmithKline |
Study Director: | GSK Clinical Trials, MD, PhD | GlaxoSmithKline |
Study ID Numbers: | NKP103401 |
First Received: | August 29, 2005 |
Last Updated: | January 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00403962 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices; South Africa: Medicines Control Council; Norway: Norwegian Medicines Agency; Denmark: Danish Medicines Agency |
|
|
|
|